Mirum Pharma Crushes Q3, Eyes $1B Sales
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Mirum Pharmaceuticals Q3 2025 report is a game-changer, with a 50% revenue surge to $133M, driven by LIVMARLI and bile acid meds. They achieved positive net income for the first time, with $92M from LIVMARLI and $41M from bile acid products. The company is now targeting the high end of their full-year guidance, with $500M-$510M in revenue. Mirums cash position is strong at $378M, and their pipeline is heating up with Phase 2 studies underway for volixibat, VANTAGE, EXPAND, and a new candidate for Fragile X syndrome. Peak sales projections for LIVMARLI, volixibat, and the new candidate exceed $1B, setting Mirum up for a high-growth future.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/9436d7b9def99405